GlassScriptPhysician profile
Dhvani Thakker
NPI 1477796175
$2,153.77
in general payments reported to CMS, 2019-2025
23 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $155 · 2021: $251 · 2022: $434 · 2023: $519 · 2024: $332 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677 · Long Term Medical Supply Or Device Loan: $299 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.60 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,012.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $334.92 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $121.32 | 2019-2025 | Keytruda |
| Janssen Biotech, INC. | $99.99 | 2019 | |
| Astellas Pharma US INC | $85.00 | 2019 | |
| Menarini Silicon Biosystems, INC. | $56.17 | 2025 | |
| Genentech USA, INC. | $52.33 | 2023-2024 | Phesgo, Itovebi, Tecentriq |
| Tactile Systems Technology INC | $45.03 | 2024 | Entre Plus, Flexitouch Plus |
| Glaxosmithkline, LLC. | $43.92 | 2021-2022 | |
| Olympus America INC. | $41.77 | 2021 | |
| Springworks Therapeutics, INC. | $30.59 | 2024 | Ogsiveo |
| Sumitomo Pharma America, INC. | $25.50 | 2024 | Gemtesa |
| Blueprint Medicines Corporation | $25.00 | 2020 | |
| Pfizer INC. | $21.00 | 2021 | |
| Seagen INC. | $20.00 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $20.00 | 2021 | |
| Lilly USA, LLC | $19.27 | 2021 | |
| Genzyme Corporation | $18.83 | 2023 | |
| Coherus Oncology, INC. | $18.79 | 2022 | |
| Incyte Corporation | $18.77 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.15 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhvani Thakker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.